Your questions, answered: What should Canadians know about lecanemab’s U.S. FDA approval?
Alberta and Northwest Territories

Important notice: Mail will be disrupted by the Canada Post strike. Please contact our administrative office to make arrangements to have correspondence sent to you by email. Phone: 1-866-950-5465 or E-mail: help@alzheimer.ab.ca